Veru (VERU) Capital Expenditures (QoQ) (2010 - 2024)
Veru (VERU) Capital Expenditures (QoQ) (2010 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -98.28% |
| Sep 30, 2024 | 15.39% |
| Jun 30, 2024 | 34.37% |
| Sep 30, 2023 | 729.14% |
| Jun 30, 2023 | -81.87% |
| Mar 31, 2023 | -50.42% |
| Dec 31, 2022 | 91.90% |
| Sep 30, 2022 | 53.71% |
| Jun 30, 2022 | -47.73% |
| Mar 31, 2022 | -38.71% |
| Dec 31, 2021 | 35.99% |
| Sep 30, 2021 | 56.17% |
| Jun 30, 2021 | 2,785.20% |
| Mar 31, 2021 | -31.37% |
| Dec 31, 2020 | -77.76% |
| Sep 30, 2020 | 72.22% |
| Jun 30, 2020 | -42.92% |
| Mar 31, 2020 | 50.75% |
| Jun 30, 2019 | 11,537.89% |
| Sep 30, 2018 | 210.82% |